RxDoctor Payments Data

Thomas Rayner, MD

Psychiatry · Provo, UTNPI 1194008979

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (44.8%), other and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 52.0% of the total. 2025 is the largest year on record at $55,446, more than ten times the $93 reported in 2022. Among psychiatry clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$60,257in general payments, 2019–2025

Across 93 payments — averaging $647.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$31K
  • Neuronetics, Inc.$28K
  • Janssen Scientific Affairs, LLC$200
  • Alkermes, Inc.$192
  • Teva Pharmaceuticals USA, Inc.$167
  • AbbVie$82
  • plus $152 from 6 others

What the payments were for

  • Speaking & faculty fees$27,02045%
  • Travel & lodging$5,0848%
  • Food & beverage$3,7786%
  • Other$24,37540%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,257 in reported general payments places this provider in the 95th percentile of 231 psychiatry providers in Utah.

See all psychiatry providers in Utah

Medicare billing

Part B allowed, 2024
$123,112
Medicare patients
102
Services billed
1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl23$35,190
Paliperidone ErPaliperidone15$5,232
Clozapine70$3,048
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$490
Duloxetine Hcl14$337
Mirtazapine40$322
Fluoxetine Hcl19$307
Quetiapine Fumarate32$206
Olanzapine14$201
Divalproex Sodium ErDivalproex Sodium15$193
Bupropion XlBupropion Hcl23$159
Lithium Carbonate48$152
Clonazepam14$142
Trazodone Hcl21$127
Glycopyrrolate14$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$31,350$35,19023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 231 psychiatry providers in Utah.

Other psychiatry in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →